Sphera Funds Management LTD Cut Its Amicus Therapeutics (FOLD) Holding; Puma Biotechnology Has 1.21 Sentiment

December 7, 2017 - By Clifton Ray

Sphera Funds Management Ltd decreased Amicus Therapeutics Inc (FOLD) stake by 20% reported in 2017Q2 SEC filing. Sphera Funds Management Ltd sold 100,000 shares as Amicus Therapeutics Inc (FOLD)’s stock rose 23.92%. The Sphera Funds Management Ltd holds 400,000 shares with $4.03M value, down from 500,000 last quarter. Amicus Therapeutics Inc now has $2.14B valuation. The stock increased 2.47% or $0.31 during the last trading session, reaching $12.85. About 657,296 shares traded. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since December 7, 2016 and is uptrending. It has underperformed by 4.25% the S&P500.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. The company has market cap of $3.82 billion. The Company’s drug candidates include PB272 ) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). It currently has negative earnings. The firm also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.

Since June 15, 2017, it had 0 insider purchases, and 1 sale for $300,000 activity. $300,000 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares were sold by Barth Jay.

Analysts await Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings on March, 7. They expect $-0.28 earnings per share, up 12.50% or $0.04 from last year’s $-0.32 per share. After $-0.41 actual earnings per share reported by Amicus Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -31.71% EPS growth.

Investors sentiment increased to 1.23 in Q2 2017. Its up 0.03, from 1.2 in 2017Q1. It improved, as 15 investors sold FOLD shares while 38 reduced holdings. 28 funds opened positions while 37 raised stakes. 168.77 million shares or 4.30% more from 161.81 million shares in 2017Q1 were reported. Rock Springs Mgmt Lp stated it has 0.39% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Aperio Llc, a California-based fund reported 13,986 shares. 55,411 were reported by Legal And General Gru Public Ltd Company. Wellington Group Inc Ltd Liability Partnership reported 5.99M shares. Moreover, Jpmorgan Chase & has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 1.28M shares. Pnc Financial Gp holds 14,907 shares or 0% of its portfolio. Cordasco Ntwk reported 140 shares. Bnp Paribas Arbitrage Sa holds 68,012 shares or 0% of its portfolio. Point72 Asset Management Limited Partnership reported 1.87M shares. Blackrock Inc reported 0.01% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). 118,800 are owned by Endurant Capital Mngmt Lp. Hightower Advisors Limited Liability stated it has 44,365 shares or 0% of all its holdings. D E Shaw & Com Incorporated holds 4.07M shares or 0.07% of its portfolio. Fred Alger Mgmt invested 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Metropolitan Life Ins Communications Ny holds 0.01% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 102,462 shares.

Among 9 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Amicus Therapeutics had 20 analyst reports since August 18, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, August 31 by Leerink Swann. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Buy” rating given on Sunday, August 13 by Cowen & Co. The company was maintained on Monday, August 7 by Cowen & Co. The firm has “Outperform” rating given on Monday, October 5 by Leerink Swann. The rating was initiated by Goldman Sachs with “Neutral” on Wednesday, March 30. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Overweight” rating by JP Morgan on Tuesday, September 8. The stock has “Outperform” rating by Robert W. Baird on Wednesday, July 12. The firm has “Neutral” rating by Chardan Capital Markets given on Wednesday, September 16. The rating was maintained by Cowen & Co with “Buy” on Sunday, June 25. The firm earned “Buy” rating on Tuesday, July 11 by Cowen & Co.

Sphera Funds Management Ltd increased Nice Ltd (NASDAQ:NICE) stake by 21,532 shares to 85,052 valued at $6.70 million in 2017Q2. It also upped Aldeyra Therapeutics Inc (NASDAQ:ALDX) stake by 207,431 shares and now owns 875,931 shares. Pieris Pharmaceuticals Inc was raised too.

Redmile Group Llc holds 4.58% of its portfolio in Puma Biotechnology, Inc. for 860,456 shares. Partner Fund Management L.P. owns 1.68 million shares or 3.96% of their US portfolio. Moreover, Partner Investment Management L.P. has 3.44% invested in the company for 29,282 shares. The New York-based Sio Capital Management Llc has invested 3.32% in the stock. Perceptive Advisors Llc, a New York-based fund reported 733,320 shares.

Analysts await Puma Biotechnology, Inc. (NASDAQ:PBYI) to report earnings on March, 7. They expect $-2.01 earnings per share, up 1.47% or $0.03 from last year’s $-2.04 per share. After $-2.07 actual earnings per share reported by Puma Biotechnology, Inc. for the previous quarter, Wall Street now forecasts -2.90% EPS growth.

Ratings analysis reveals 100% of Puma Biotech.’s analysts are positive. Out of 2 Wall Street analysts rating Puma Biotech., 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $88.0 while the high is $111.0. The stock’s average target of $99.50 is -2.31% below today’s ($101.85) share price. PBYI was included in 2 notes of analysts from September 21, 2016. The stock has “Outperform” rating by Credit Suisse on Thursday, September 22. The rating was upgraded by Stifel Nicolaus to “Buy” on Wednesday, September 21.

The stock increased 3.88% or $3.8 during the last trading session, reaching $101.85. About 273,973 shares traded. Puma Biotechnology, Inc. (PBYI) has risen 23.65% since December 7, 2016 and is uptrending. It has outperformed by 6.95% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.